How LUTATHERA® (lutetium Lu 177 dotatate) May Help

Effectiveness of LUTATHERA

In a clinical trial of 229 patients that compared patients with midgut neuroendocrine tumors (NETs) who received LUTATHERA in combination with 30-mg, long-acting octreotide to those who received 60 mg of long-acting octreotide alone:

  • LUTATHERA reduced the relative risk of the cancer getting worse or death by 79% compared with patients treated with 60 mg of long-acting octreotide alone
  • More patients treated with LUTATHERA had their tumors shrink or disappear compared with patients treated with 60 mg of long-acting octreotide alone.1

Percent of patients who had their tumors shrink or disappear

Partial Response (tumors shrink): Tumor shrinks by at least 30%, but does not disappear.

12% (14 of 116 patients)

Complete Response (tumors disappear):Tumor shrinks until it is too small to be seen using medical imaging.

1% (1 of 116 patients)

Partial Response (tumors shrink):Tumor shrinks by at least 30%, but does not disappear.

4% (4 of 113 patients)

Complete Response (tumors disappear):Tumor shrinks until it is too small to be seen using medical imaging.

0% (0 of 113 patients)

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

home_logo
Patient Discussion Guide
You are now leaving the LUTATHERA.com website. Advanced Accelerator Applications USA, Inc. is not responsible for the content on external websites.